Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region

Until recently, international and Asia‐specific guidelines for advanced urothelial carcinoma (UC) recommended first‐line (1L) platinum‐based chemotherapy, followed by second‐line (2L) anti‐PD‐1 or anti‐PD‐L1 immune checkpoint inhibitor (ICI) therapy where possible, or 1L ICI therapy in cisplatin‐ine...

Descripción completa

Detalles Bibliográficos
Autores principales: Eto, Masatoshi, Lee, Jae‐Lyun, Chang, Yen‐Hwa, Gao, Seasea, Singh, Manmohan, Gurney, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542411/
https://www.ncbi.nlm.nih.gov/pubmed/35238147
http://dx.doi.org/10.1111/ajco.13765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542411/
https://www.ncbi.nlm.nih.gov/pubmed/35238147
http://dx.doi.org/10.1111/ajco.13765

Ejemplares similares